Advanced Malignant Solid Tumor Clinical Trial
Official title:
A Dose Escalation, Open-label Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 in the Treatment of Patients With Advanced Malignant Solid Tumors
VG2025 is a Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection. This Phase I study will be conducted in herpes simplex virus (HSV) -seropositive subjects with advanced malignant solid tumors that are refractory to conventional therapies. This is an open label study to determine the safety and tolerability of VG2025, and recommended dose of VG2025 for Phase II trials.
This is a Phase 1, open-label, dose-escalation trial using standard 3+3 dose-escalation design in patients with advanced malignant solid tumors. The trial will be conducted in multiple dosing cohorts, and evaluated for safety to determine the Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D). Dose limiting toxicity (DLT) evaluation period is for 4 weeks from the start of treatment Day 1 through Day 28. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04864379 -
Clinical Study of a Personalized Neoantigen Cancer Vaccine Combined With Anti-PD-1 and RFA in Patients With Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04165590 -
Plasmodium Immunotherapy for Advanced Malignant Solid Tumors
|
Phase 1/Phase 2 | |
| Terminated |
NCT05098405 -
First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT06150183 -
Safety and Preliminary Efficacy of BNT314 With or Without an Immune Checkpoint Inhibitor in Cancer Patients With Malignant Solid Tumors
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05911984 -
A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Preliminary Efficacy of 9MW3811 in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05396339 -
A Clinical Trial to Evaluate the Effect of IAE0972 in Patients With Advanced Malignant Solid Tumors.
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03171220 -
Neoantigen Reactive T Cells Combined With SHR-1210 for Chinese Patients With Advanced Refractory Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04241835 -
A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function
|
Phase 1 | |
| Active, not recruiting |
NCT03662815 -
Clinical Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Malignant Tumor
|
Phase 1 | |
| Not yet recruiting |
NCT06166472 -
A Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of AK132 in Advanced Malignant Solid Tumor
|
Phase 1 | |
| Not yet recruiting |
NCT04275050 -
A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3303 Tablets
|
Phase 1 | |
| Recruiting |
NCT04758897 -
Clinical Study of VG161 in Subjects With Advanced Malignant Solid Tumors
|
Phase 1 |